# A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.

> **NCT05178550** · EARLY_PHASE1 · COMPLETED · sponsor: **Novo Nordisk A/S** · enrollment: 12 (actual)

## Conditions studied

- Healthy Volunteers

## Interventions

- **DRUG:** Heparin

## Key facts

- **NCT ID:** NCT05178550
- **Lead sponsor:** Novo Nordisk A/S
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-17
- **Primary completion:** 2022-01-11
- **Final completion:** 2022-01-17
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2023-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05178550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05178550, "A Study in Healthy Participants Investigating Biomarkers After Exposure to Heparin When Heparin is Administered in the Fasted State or After a High-fat Meal. Heparin, a Registered Drug, is an Anticoagulant (Blood Thinner) That Prevents the Formation of Blood Clots.". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05178550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*